Xadpx
RankingsLogo

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing RNA interference therapeutics to treat genetic illnesses.

Ticker: ALNY

Humankind Value: $47.6 B

Revenue: $2.2 B

Market Cap: $33.7 B

Badge100_2025
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Alnylam Pharmaceuticals, Inc., notably a company that operates at a loss, generates positive Humankind Value on balance. Considerable positive value is associated with Healthcare R&D ($45.8 B), Pharmaceuticals ($2.1 B), and Medical Services ($43.8 M). Positive value from Healthcare R&D, Pharmaceuticals, and Medical Services is linked to an estimate of 910,000 additional years lived by people worldwide. The Humankind Value of this company can improve with reductions in Greenhouse Gases (-$45.3 M) and Air Pollution (-$4.9 M). Healthcare R&D, Pharmaceuticals, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities. Medical Services is largely a consequence of the actions of its supply chain partners.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings